PriceTargets.com logo

Scholar Rock - SRRK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.43
  • Forecasted Upside: 3.50%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$39.06 As of 12/3/2024 12:32 PM ET
▲ +1.1 (2.90%)

This chart shows the closing price for SRRK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Scholar Rock Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRRK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRRK

Analyst Price Target is $40.43
▲ +3.50% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Scholar Rock in the last 3 months. The average price target is $40.43, with a high forecast of $50.00 and a low forecast of $30.00. The average price target represents a 3.50% upside from the last price of $39.06.

This chart shows the closing price for SRRK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Scholar Rock. This rating has held steady since December 2022, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/26/2024HC WainwrightBoost TargetBuy ➝ Buy$40.00 ➝ $50.00
11/25/2024WedbushBoost TargetOutperform ➝ Outperform$40.00 ➝ $47.00
11/25/2024Truist FinancialBoost TargetBuy ➝ Buy$36.00 ➝ $45.00
11/12/2024HC WainwrightBoost TargetBuy ➝ Buy$35.00 ➝ $40.00
11/4/2024WedbushReiterated RatingOutperform$37.00
10/15/2024Piper SandlerBoost TargetOverweight ➝ Overweight$28.00 ➝ $42.00
10/14/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$18.00 ➝ $31.00
10/11/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$34.00 ➝ $38.00
10/7/2024WedbushBoost TargetOutperform ➝ Outperform$27.00 ➝ $37.00
10/7/2024HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $35.00
10/3/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$20.00 ➝ $18.00
8/9/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$31.00 ➝ $34.00
8/8/2024WedbushReiterated RatingOutperform$23.00
6/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
6/13/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$29.00 ➝ $31.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
5/7/2024WedbushReiterated RatingOutperform$23.00
4/3/2024Truist FinancialReiterated RatingBuy ➝ Buy$20.00
3/28/2024Raymond JamesInitiated CoverageStrong-Buy$30.00
3/26/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$28.00
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$20.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
1/23/2024WedbushReiterated RatingOutperform$23.00
1/4/2024WedbushReiterated RatingOutperform$23.00
10/31/2023WedbushReiterated RatingOutperform$23.00
10/25/2023Jefferies Financial GroupUpgradeHold ➝ Buy$20.00
10/12/2023WedbushLower Target$24.00 ➝ $23.00
10/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
4/3/2023Piper SandlerReiterated RatingOverweight$26.00
3/8/2023HC WainwrightReiterated RatingBuy$30.00
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$38.00 ➝ $20.00
11/15/2022BMO Capital MarketsLower TargetOutperform$43.00 ➝ $32.00
9/19/2022HC WainwrightReiterated RatingBuy$30.00
8/9/2022BMO Capital MarketsLower Target$55.00 ➝ $43.00
7/12/2022Truist FinancialInitiated CoverageBuy$20.00
6/23/2022Piper SandlerLower TargetOverweight$28.00 ➝ $19.00
5/24/2022JPMorgan Chase & Co.Lower Target$46.00 ➝ $37.00
5/17/2022WedbushLower TargetNA$50.00 ➝ $33.00
5/17/2022BMO Capital MarketsLower Target$74.00 ➝ $55.00
5/16/2022Piper SandlerLower TargetOverweight$56.00 ➝ $28.00
3/23/2022HC WainwrightInitiated CoverageBuy$24.00
3/7/2022WedbushReiterated RatingOutperform$50.00
12/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$52.00 ➝ $28.00
11/18/2021Piper SandlerInitiated CoverageOverweight$56.00
1/25/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$54.00 ➝ $79.00
1/21/2021WedbushBoost TargetOutperform$47.00 ➝ $66.00
1/11/2021Credit Suisse GroupInitiated CoverageOutperform$65.00
1/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$59.00
11/10/2020WedbushBoost TargetPositive ➝ Outperform$33.00 ➝ $47.00
10/28/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$33.00 ➝ $52.00
10/27/2020Robert W. BairdReiterated RatingOutperform$35.00 ➝ $39.00
6/29/2020BMO Capital MarketsReiterated RatingBuy$33.00
3/11/2020Robert W. BairdInitiated CoverageOutperform$35.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 8 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/4/2024
  • 24 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 19 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 19 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $39.06
Low: $37.38
High: $39.13

50 Day Range

MA: $26.08
Low: $7.07
High: $39.90

52 Week Range

Now: $39.06
Low: $6.76
High: $43.38

Volume

123,449 shs

Average Volume

1,146,619 shs

Market Capitalization

$3.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Scholar Rock?

The following Wall Street research analysts have issued research reports on Scholar Rock in the last twelve months: BMO Capital Markets, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Raymond James, Truist Financial Co., and Wedbush.
View the latest analyst ratings for SRRK.

What is the current price target for Scholar Rock?

0 Wall Street analysts have set twelve-month price targets for Scholar Rock in the last year. Their average twelve-month price target is $40.43, suggesting a possible upside of 3.5%. HC Wainwright has the highest price target set, predicting SRRK will reach $50.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $30.00 for Scholar Rock in the next year.
View the latest price targets for SRRK.

What is the current consensus analyst rating for Scholar Rock?

Scholar Rock currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRRK will outperform the market and that investors should add to their positions of Scholar Rock.
View the latest ratings for SRRK.

What other companies compete with Scholar Rock?

Other companies that are similar to Scholar Rock include Summit Therapeutics, Sarepta Therapeutics, Dr. Reddy's Laboratories, Vaxcyte and Catalent. Learn More about companies similar to Scholar Rock.

How do I contact Scholar Rock's investor relations team?

Scholar Rock's physical mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 259-3860 and its investor relations email address is [email protected]. The official website for Scholar Rock is www.scholarrock.com. Learn More about contacing Scholar Rock investor relations.